The Idea

Our mission is to develop innovative treatments for diseases characterized by disproportional activation of inflammation, leveraging the body’s natural defense system as a template.

The Need

Inflammatory diseases are major threats to human health and are associated with significant mortality as well as costs for society. According to the World Health Organization (WHO) three out of five people die because of chronic inflammatory diseases including diseases such as stroke, chronic respiratory diseases, heart disorders, obesity, cancer, and diabetes.

The Solution

Our primary drug candidate TIM-03, is a designed peptide based on the structure of natural Thrombin-derived C-terminal peptides (TCPs) with potentially broad utility as a treatment for inflammatory diseases.

"With its unique mode of action, TIM-03 stands out as a promising drug candidate, addressing the significant unmet need for effective treatments across a wide range of inflammatory diseases."

Helene Hartman, CEO Transient Pharma AB

News

Upcoming Events

Meet us at BIO-Europe in Stockholm!

4 - 6 November, 2024

BIO-Europe, Europe’s leading partnering event, provides an opportunity to connect with potential partners and investors spanning the global life science ecosystem. We plan to attend, and we are happy to meet you there.

Register

Scientific Publications

Explore our publications on Thrombin-derived C-terminal Peptides (TCPs), their mode of action and efficacy in vitro and in vivo.

To Publications